Biomarker Testing and Clinical Trial Enrollment in NSCLC: Retrospective Analysis of Racial Disparities

June 4-8, 2021; Online at
Multivariable regression analyses of deidentified health record data showed that Black patients with NSCLC were less likely to receive NGS-based genetic testing or enroll on clinical trials than White patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 465 KB
Released: June 15, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

In this on-demand webcast from CCO, Mary Jo Fidler, MD, and Scott Gettinger, MD, review the latest advances in immunotherapy for NSCLC through discussion of a series of patient cases.

person default Mary Jo Fidler, MD person default Scott Gettinger, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 15, 2021 Expired: July 14, 2022

Download this short slideset for an overview of the current status of biomarkers guiding optimal use of targeted therapy and immunotherapy in the treatment of advanced NSCLC, from CCO

Stephen V. Liu, MD Suresh S. Ramalingam, MD, FACP, FASCO Lecia V. Sequist, MD, MPH Released: July 8, 2021

Video from Clinical Care Options (CCO) featuring latest guidance in the diagnosis and treatment of patients with NTRK fusion positive cancers.

George D. Demetri, MD
Program Director
Alexander Drilon, MD Theodore Laetsch, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 7, 2021 Expired: July 6, 2022

Downloadable summary slideset from a live CCO Webinar on recent advances in immunotherapy for the treatment of patients with early and advanced NSCLC

person default Mary Jo Fidler, MD person default Scott Gettinger, MD Released: July 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.